Publications by authors named "T Gomez-Isla"
Background: Some individuals can tolerate the presence of Alzheimer disease neuropathologic changes (ADNC) (e.g., plaques and tangles) without developing dementia.
View Article and Find Full Text PDFArticle Synopsis
- Portable low-field magnetic resonance imaging (LF-MRI) offers a promising way to assess Alzheimer's disease (AD) patients in places where traditional MRI isn't available, despite some limitations in image quality.
- * Researchers optimized LF-MRI techniques and created a free machine learning tool for analyzing brain structure and white matter changes in patients with cognitive impairments.
- * The study found that LF-MRI accurately measures hippocampal volumes and white matter hyperintensities, suggesting that this technology can improve access to neuroimaging for dementia patients at a lower cost.
Proteins exhibiting prion-like properties are implicated in tauopathies. The prion-like traits of tau influence disease progression and correlate with severity. Techniques to measure tau bioactivity such as RT-QuIC and biosensor cells lack spatial specificity.
View Article and Find Full Text PDFWe and others have shown that [F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in Alzheimer's (AD) but has relatively low affinity for tau aggregates in non-AD tauopathies and exhibits off-target binding to neuromelanin- and melanin-containing cells, and to hemorrhages. Several second-generation tau tracers have been subsequently developed. [F]-MK-6240 and [F]-PI-2620 are the two that have garnered most attention.
View Article and Find Full Text PDFImportance: Factors associated with synapse loss beyond amyloid-β plaques and neurofibrillary tangles may more closely correlate with the emergence of cognitive deficits in Alzheimer disease (AD) and be relevant for early therapeutic intervention.
Objective: To investigate whether accumulation of tau oligomers in synapses is associated with excessive synapse elimination by microglia or astrocytes and with cognitive outcomes (dementia vs no dementia [hereinafter termed resilient]) of individuals with equal burdens of AD neuropathologic changes at autopsy.
Design, Setting, And Participants: This cross-sectional postmortem study included 40 human brains from the Massachusetts Alzheimer Disease Research Center Brain Bank with Braak III to IV stages of tau pathology but divergent antemortem cognition (dementia vs resilient) and cognitively normal controls with negligible AD neuropathologic changes.